Levetiracetam Injection
Product Images NDC 72485-106

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 72485-106). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Armas Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Carton (7248510610)

Levetiracetam Injection, USP 500 mg/5 mL (100 mg/mL) intravenous injection by Armas Pharmaceuticals Inc. The carton contains 10 single-dose 5 mL vials. The label specifies use for intravenous administration only and indicates the product must be diluted prior to administration. Manufactured by Micro Labs Limited, India, and distributed by Armas Pharmaceuticals in New Jersey, USA.*

FDA Label Image

Fig 1 (Levitiracetamfigure1)

A bar chart showing the percentage of patients for different treatment groups: Placebo (7.4%), Levetiracetam 1000 mg/day (37.1%), and Levetiracetam 3000 mg/day (39.6%). The y-axis represents the percentage of patients (0% to 45%), and each bar is labeled with the group size (N) below the x-axis. Asterisks mark the Levetiracetam groups.*

FDA Label Image

Fig 2 (Levitiracetamfigure2)

A bar chart showing the percentage of patients for three groups: Placebo (6.3%), Levetiracetam 1000 mg/day (20.8%), and Levetiracetam 2000 mg/day (35.2%). The x-axis categorizes the treatment groups including sample sizes, and the y-axis represents the percentage of patients from 0% to 45%.*

FDA Label Image

Fig 3 (Levitiracetamfigure3)

Bar chart comparing the percentage of patients experiencing a specific outcome between Placebo (N=104) and Levetiracetam 3000 mg/day (N=108). The chart shows 14.4% for Placebo and 39.4% for Levetiracetam 3000 mg/day along the vertical axis labeled '% of Patients.'*

FDA Label Image

Fig 4 (Levitiracetamfigure4)

A bar graph comparing the percentage of patients for Placebo (N=97) and Levetiracetam (N=101). The Placebo group shows 19.6% of patients, and the Levetiracetam group shows 44.6% of patients. The vertical axis represents the percentage of patients, ranging from 0% to 45%.*

FDA Label Image

Fig 5 (Levitiracetamfigure5)

A vertical bar chart comparing the percentage of patients between Placebo (N=51) and Levetiracetam (N=58). The vertical axis represents the percentage of patients from 0% to 45%. The Placebo group shows 19.6%, while the Levetiracetam group shows 43.1%. An asterisk is displayed within the Levetiracetam bar.*

FDA Label Image

Fig 6 (Levitiracetamfigure6)

A bar chart comparing the percentage of patients between two groups: Placebo (N=84) and Levetiracetam (N=79). The y-axis represents the percentage of patients, showing 45.2% for the placebo group and 72.2% for the Levetiracetam group.*

FDA Label Image

Structure (Levitiracetamstrc)

Chemical structure of Levetiracetam showing the molecular arrangement including a pyrrolidone ring and side chains with ethyl and amide groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.